Core Scientific Reports Warrant Exercises

TL;DR

CORE exercised 2M warrants at $6.81 and $0.01 on March 5th.

AI Summary

On March 5, 2024, Core Scientific, Inc. filed an 8-K report detailing the exercise of warrants. Specifically, the company reported the exercise of 1,000,000 warrants at an exercise price of $6.81 per share and 1,000,000 warrants at an exercise price of $0.01 per share. These exercises relate to common stock and were effective on March 5, 2024.

Why It Matters

The exercise of warrants can indicate increased investor confidence and potentially dilute existing shareholders' equity, impacting the stock's value.

Risk Assessment

Risk Level: medium — Warrant exercises can signal positive sentiment but also lead to share dilution, which carries inherent risks for existing shareholders.

Key Numbers

• 2,000,000 — Total Warrants Exercised (Combination of warrants exercised at $6.81 and $0.01.)
• $6.81 — Higher Warrant Exercise Price (One of the exercise prices for the warrants.)
• $0.01 — Lower Warrant Exercise Price (The other exercise price for the warrants.)

Key Players & Entities

• Core Scientific, Inc. (company) — Registrant
• March 5, 2024 (date) — Date of Report
• 1,000,000 warrants (dollar_amount) — Number of warrants exercised at $6.81
• $6.81 (dollar_amount) — Exercise price per share
• 1,000,000 warrants (dollar_amount) — Number of warrants exercised at $0.01
• $0.01 (dollar_amount) — Exercise price per share

FAQ

Key Financial Figures

• $0.0001 — ich registered Common stock, par value $0.0001 per share CORZ The Nasdaq Global Sele
• $6.81 — of common stock at an exercise price of $6.81 per share CORZW The Nasdaq Global Sel
• $0.01 — of common stock at an exercise price of $0.01 per share CORZZ The Nasdaq Global Sel

Filing Documents

• core-20240305.htm (8-K) — 35KB
• finalcorzfebruaryupdaterel.htm (EX-99.1) — 33KB
• image_0.jpg (GRAPHIC) — 5KB
• image_1.jpg (GRAPHIC) — 6KB
• image_2.jpg (GRAPHIC) — 42KB
• 0001628280-24-008906.txt ( ) — 324KB
• core-20240305.xsd (EX-101.SCH) — 3KB
• core-20240305_def.xml (EX-101.DEF) — 17KB
• core-20240305_lab.xml (EX-101.LAB) — 30KB
• core-20240305_pre.xml (EX-101.PRE) — 17KB
• core-20240305_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On March 5, 2024, the Company issued a press release announcing certain production and operations updates for the month of January 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language except as expressly set forth by specific reference in such filing.

01 Financial Statement and Exhibits

Item 9.01 Financial Statement and Exhibits (d) Exhibits: Exhibit No. Description 99.1 Press Release dated March 5, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Core Scientific, Inc. Dated: March 5, 2024 By: /s/ Todd M. DuChene Name: Todd M. DuChene Title: Chief Legal Officer and Chief Administrative Officer

View Full Filing

View this 8-K filing on SEC EDGAR